Pharma BD Deal Intelligence
Built the world's #1 generics company, then Novartis exited the whole thing 18 years later via spinoff after an antitrust scandal and margin erosion
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Mixed analyst views — Sal. Oppenheim's Birgit Kulhoff voiced skepticism about structural pricing problems in Germany and the US, while Lombard Odier's Bob…
Sandoz wrests top generic slot from Teva — combined entity gains 600+ APIs across 5,000+ dosage forms and a 70-product 2005 US/Germany launch slate.
European Commission cleared the Novartis/Hexal merger after Phase I review, finding the combined entity would not significantly impede effective competition in…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Novartis announces simultaneous acquisitions of Hexal (~$5.65B EUR) and Eon Labs ($1.72B equity + tender) creating world's largest generics player (Sandoz). Combined value ~$8.4B.
Built the world's #1 generics company, then Novartis exited the whole thing 18 years later via spinoff after an antitrust scandal and margin erosion
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Hexal AG and Eon Labs Inc. (this deal) | 2005 | $8.4B | 48 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2005 deals · Novartis AG deals